BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21493591)

  • 1. Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-β and valproic acid.
    Roos WP; Jöst E; Belohlavek C; Nagel G; Fritz G; Kaina B
    Cancer Res; 2011 Jun; 71(12):4150-60. PubMed ID: 21493591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
    Naumann SC; Roos WP; Jöst E; Belohlavek C; Lennerz V; Schmidt CW; Christmann M; Kaina B
    Br J Cancer; 2009 Jan; 100(2):322-33. PubMed ID: 19127257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.
    Eich M; Roos WP; Nikolova T; Kaina B
    Mol Cancer Ther; 2013 Nov; 12(11):2529-40. PubMed ID: 23960094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.
    Roos WP; Batista LF; Naumann SC; Wick W; Weller M; Menck CF; Kaina B
    Oncogene; 2007 Jan; 26(2):186-97. PubMed ID: 16819506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death.
    Zhang J; Hummersone M; Matthews CS; Stevens MF; Bradshaw TD
    Oncology; 2015; 88(1):28-48. PubMed ID: 25277441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.
    Krumm A; Barckhausen C; Kücük P; Tomaszowski KH; Loquai C; Fahrer J; Krämer OH; Kaina B; Roos WP
    Cancer Res; 2016 May; 76(10):3067-77. PubMed ID: 26980768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1.
    Roos W; Baumgartner M; Kaina B
    Oncogene; 2004 Jan; 23(2):359-67. PubMed ID: 14724564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoic acid inhibits the DNA repair protein O 6-methylguanine-DNA methyltransferase (MGMT) and triggers its depletion in colorectal cancer cells with concomitant autophagy induction.
    Göder A; Nagel G; Kraus A; Dörsam B; Seiwert N; Kaina B; Fahrer J
    Carcinogenesis; 2015 Aug; 36(8):817-31. PubMed ID: 25998848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide.
    Eich M; Roos WP; Dianov GL; Digweed M; Kaina B
    Mol Pharmacol; 2010 Nov; 78(5):943-51. PubMed ID: 20729302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
    Wagner LM; McLendon RE; Yoon KJ; Weiss BD; Billups CA; Danks MK
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5418-25. PubMed ID: 17875772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines.
    Chen YP; Hou XY; Yang CS; Jiang XX; Yang M; Xu XF; Feng SX; Liu YQ; Jiang G
    Tumour Biol; 2016 Aug; 37(8):11209-18. PubMed ID: 26943799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution.
    Boeckmann L; Nickel AC; Kuschal C; Schaefer A; Thoms KM; Schön MP; Thomale J; Emmert S
    Melanoma Res; 2011 Jun; 21(3):206-16. PubMed ID: 21460749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
    Zheng M; Bocangel D; Ramesh R; Ekmekcioglu S; Poindexter N; Grimm EA; Chada S
    Mol Cancer Ther; 2008 Dec; 7(12):3842-51. PubMed ID: 19056673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells.
    Happold C; Roth P; Silginer M; Florea AM; Lamszus K; Frei K; Deenen R; Reifenberger G; Weller M
    Mol Cancer Ther; 2014 Apr; 13(4):948-61. PubMed ID: 24526161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors.
    Tomaszowski KH; Schirrmacher R; Kaina B
    Mol Pharm; 2015 Nov; 12(11):3924-34. PubMed ID: 26379107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
    Jiang G; Wei ZP; Pei DS; Xin Y; Liu YQ; Zheng JN
    Biochem Biophys Res Commun; 2011 Mar; 406(3):311-4. PubMed ID: 21329652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.
    Ramcharan R; Aleksic T; Kamdoum WP; Gao S; Pfister SX; Tanner J; Bridges E; Asher R; Watson AJ; Margison GP; Woodcock M; Repapi E; Li JL; Middleton MR; Macaulay VM
    Oncotarget; 2015 Nov; 6(37):39877-90. PubMed ID: 26497996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.
    Kaina B; Christmann M; Naumann S; Roos WP
    DNA Repair (Amst); 2007 Aug; 6(8):1079-99. PubMed ID: 17485253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
    Spiro T; Liu L; Gerson S
    Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
    Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C
    Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.